A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
The first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon Therapeutics’ lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results